Status:
TERMINATED
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
Detailed Description
A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, parallel Group Study to Assess the Efficacy and Safety of AZD2066 after 6 weeks of treatment in Patien...
Eligibility Criteria
Inclusion
- Provision of signed, written, and dated Informed Consent
- Documented primary clinical diagnosis of Major Depressive Disorder
Exclusion
- Patients with a secondary psychiatric disorder including bipolar disorder, psychotic disorders (i.e. schizophrenia, schizoaffective disorder, depression with psychotic features), GAD and social anxiety disorder
- Patients whose current episode of depression started less than 4 weeks before enrollment
- History of inadequate response of antidepressants during current depressive episode
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT01145755
Start Date
May 1 2010
End Date
November 1 2010
Last Update
October 3 2012
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Garden Grove, California, United States
2
Research Site
San Diego, California, United States
3
Research Site
Jacksonville, Florida, United States
4
Research Site
Atlanta, Georgia, United States